On 26 May 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A14-49 (Tafluprost / timolol – Benefit assessment according to §35a SGB V).
http://ift.tt/2seExXK
Πέμπτη 15 Ιουνίου 2017
Tafluprost / Timolol (Addendum to Commission A14-49) [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου